Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 15,555

Document Document Title
WO/2018/011578A1
This invention relates to a process for the preparation of Form B of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. Also disclosed herein is Form B of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopro...  
WO/2018/011579A1
This invention relates to a process for the preparation of Form A of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. Also disclosed herein is Form A of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopro...  
WO/2018/005678A1
The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivati...  
WO/2018/001973A1
The present invention relates to pyrazole derivatives of formula (I) having pharmacological activity towards the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel, in particular having dual pharmacolo...  
WO/2017/219083A1
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...  
WO/2017/219805A1
Provided are a compounded weeding composition containing dicarfentrazone-ethyl, and a using method therefor. The compounded weeding composition comprises an active component A and an active component B, the active component A is dicarfen...  
WO/2017/217553A1
[Problem] To provide a novel agricultural chemical, and particularly an herbicide. [Solution] An oxime compound represented by formula (1) and an herbicide containing the same. (In formula (1): B represents B-1 or the like; Q represents ...  
WO/2017/210792A1
The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare- ups, and/or reduce the severity of flare...  
WO/2017/202884A1
The present invention relates to novel 1-hexyl-1H-pyrazole-4,5-diamine derivative compounds of formula (I), to a composition for oxidation dyeing of the keratin fibres containing same, to a process for preparing the compounds of formula ...  
WO/2017/205296A1
2-Acylindazole compounds of formula I or formula II are disclosed. These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.  
WO/2017/202896A1
The invention provides novel compounds having the general formula (I) wherein R1, R1', R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2017/205795A1
The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.  
WO/2017/201581A1
The present invention relates to new desferrioxamine B-based compounds that may be useful to treat neurodegenerative diseases, to their preparation, and to compositions including the compounds. The present invention also relates to the u...  
WO/2017/197509A1
The present application is directed to transdermal formulations for the delivery of celecoxib to a subject for the treatment of celecoxib-responsive diseases or conditions. In particular, the transdermal formulation is an emulsion compri...  
WO/2017/201161A1
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and me...  
WO/2017/196936A1
Disclosed are Indole and Indazole cyanocinnamate compounds, method for preparing these compounds, and methods for treating cancer.  
WO/2017/195216A1
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...  
WO/2017/197083A1
Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H- pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to he...  
WO/2017/194517A1
The present invention concerns compositions comprising (i) a 3-(haloalkyl or formyl)-1H-pyrazole wherein R1 is a halogenated C1-4alkyl group, or the group -C(O)H, R2 is selected from the group consisting of H, C1-C12 alkyl, C2-C6 alkenyl...  
WO/2017/193034A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/191000A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2017/193041A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/191098A1
Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.  
WO/2017/192290A1
In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress...  
WO/2017/193063A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/190086A1
Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathw...  
WO/2017/190028A1
Methods for treating cancers, such as breast cancer or skin cancer, using an ACE or ARB, or a combination of celecoxib and olmesartan.  
WO/2017/184604A1
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2017/184658A1
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.  
WO/2017/181177A1
The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia)...  
WO/2017/180577A1
The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.  
WO/2017/180528A1
Methods for treating a CB2 receptor-related disorder (e.g., pain, fibrosis) are provided. These methods are directed to reducing the risk of adverse events based on reduced blood pressure and/or heart rate in subjects in need of treatmen...  
WO/2017/171657A1
A device and a method for detection of an acryloyl group in a sample are provided. The device comprises a first device coupleable to a second device having a transceiver and a camera for detection of an acryloyl group in a sample, the fi...  
WO/2017/171053A1
The present invention provides a pharmaceutical composition for the treatment or prevention of synucleinopathy, the pharmaceutical composition including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.  
WO/2017/165300A1
Disclosed are Indole and Indazole derivatives, method for preparing these compounds, and methods for treating cancers.  
WO/2017/163263A1
The present invention provides novel indole derivatives of formula (I), I Wherein, R, R1 and R2 is independently selected from halo, nitro, methoxy, alkyl, thiomethyl, alkyl, aryl, substituted aryl, cyano, cycloalkyl, -COO, amide; and X ...  
WO/2017/165256A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2017/162007A1
The present invention relates to an aromatic amide derivative and a preparation method and medicinal application thereof. Specifically, the present invention relates to a novel derivative represented by general formula (I) and a pharmace...  
WO/2017/160922A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/160930A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/161325A1
The present invention provides tools and methods for the systematic analysis of genetic interactions between cells. The present invention provides tools and methods for modulating cell phenotypes and compositions, combinatorial probing o...  
WO/2017/160069A1
The present invention relates to a novel benzenesulfonamide derivative or a pharmaceutically acceptable salt thereof and a use thereof and, more specifically, to a novel benzenesulfonamide derivative having a mammalian target of rapamyci...  
WO/2017/155942A3
Disclosed are substituted heterocycles compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be util...  
WO/2017/153952A1
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. ...  
WO/2017/156495A1
Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.  
WO/2017/155050A1
Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity. A compound represented by formula (I) [wherein each symbol is as defined in the description] or a salt thereof has a cholinergic m...  
WO/2017/151802A1
A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB 1 receptor mediating scaffold and (ii) a second therapeutic scaffold.  
WO/2017/143230A1
Provided herein are compounds (e.g., compounds of Formulae (I), (II), and (III)) which are anti-fungal agents and can be used in the treatment of diseases, including infectious diseases. The invention provides methods of treating disease...  
WO/2017/140593A1
The present invention concerns a process for the manufacture of carboxamides, in particular agrochemical or pharmaceutically active ingredients, from pyrazole ketone compounds.  
WO/2017/140778A1
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently...  

Matches 1 - 50 out of 15,555